Abata Therapeutics to Present at Upcoming Investor and Industry Events in June
external-link
A Life in Biotech & the Cell Therapy Wave: David Hallal on The Long Run - Timmerman Report
external-link
9 Story Building at Arsenal Yards Fully Leased, 5 Life Science Tenants Coming 100 Forge - Watertown News
external-link
1st Abata Candidate Will Be T-cell Therapy ABA-101 for Progressive MS - Multiple Sclerosis News Today
external-link
Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells to Treat Serious Autoimmune and Inflammatory Diseases - Business Wire
external-link
Our new CTO, Joanne Tzouvalopoulos Beck’s take on joining Abata and her excitement surrounding our groundbreaking partnership with ElevateBio to support clinical advancement and pipeline expansion.
L
external-link
Mar 2023
Opinion & Video: A new MRI technique gives insight into mechanisms underlaying MS progr
external-link
Preclinical Development of a T Cell Receptor Engineered Regulatory T Cell (Treg) Therapy for Progressive Pathology in MS
ACTRIMS 2024 Poster
February 29, 2024
external-link
New investment to advance Abata’s T-cell therapy for progressive MS - Multiple Sclerosis News Today
external-link
Sept 2010
Demonstration of Treg stability in vivo in the presence of inflammatory autoimmune con
external-link
Third Rock-backed startup launches to develop cell therapies for MS, diabetes - BioPharma Dive
external-link
In Vivo Nonclinical Evaluation of Activity and Safety of a T Cell Receptor Engineered Regulatory T Cell Therapy for MS Progression Independent of Relapse Activity
ECTRIMS 2024
external-link
Cell therapy weekly: US FDA grants Orphan Drug Designation to a gene therapy for a type of retinal disease - RegMedNet
external-link
In this article with the National MS Society, our CEO Samantha Singer shares her deeply personal journey with multiple sclerosis.
Her story is a testament to the life-changing impact of treatments th
external-link
In September, we added three amazing new employees, including Joanne Tzouvalopoulos Beck, our new CTO, Loundja BENSEGHIR, our AD of Quality Assurance and Surbhi Kansagara, Sr. Research Assoc. We are t
external-link
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development - GlobeNewswire
external-link
Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors
external-link
Feb 2022
Demonstration that meningeal inflammation is associated with chronic-active white matte
external-link
2004
Demonstration that antigen-specific Tregs are much more effective than polyclonal Tregs in
external-link
Functional Characterization of Regulatory T cell (Treg) Therapy for the Treatment of Type 1 Diabetes (T1D)
nPOD 2024 Poster
February 19, 2024
external-link
Abata Therapeutics announces equity investment from Bristol Myers
external-link
Fun-filled time at the Ragnar Sprint Reach the Beach race where our amazing team of Abatars hit the ground running for the third year in a row.
Our 3-person ultra-team placed first in the ultra-spr
external-link
Mar 2024
Harnessing regulatory T cells to establish immune tolerance
external-link
At this time of year, we reflect on one of our core values – "Strengthened by Differences" – as we come together to celebrate Diversity Awareness Month and the upcoming holiday season. Our annual potl
external-link
BioTechnology Innovators Honored in 3rd Annual BioTech ...
external-link
Last month we added an incredible new Principal Scientist to the team - Stephanie Morgan! We’re excited to have Stephanie on board as we look forward to a momentum-filled end of 2024 and beyond! Welco
external-link
Venture Report: Halda bringing RIPTACs into clinic with crossover round - BioCentury
external-link
Sept 2012
Review: T cells circulate through the cerebrospinal fluid in the meningeal compartment
external-link
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
external-link
Unveiling Novel T-cell Receptors (TCRs) for Enhanced Treg Cell Therapy in Type 1 Diabetes (T1D)
nPOD 2024 Poster
February 19, 2024
external-link
Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events
Press Release
August 28, 2023
external-link
Abata hopes to find 'perfect fit' with MS cell therapy after ...
external-link
2003
Demonstration that FoxP3 functions as a key driver of Treg development and phenotype.
external-link
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
external-link
Abata Therapeutics Receives FDA Fast Track Designation for - GlobeNewswire
external-link
Top 10 US Biopharma Series A Rounds of 2021 – So Far! - BioSpace
external-link
Sep 2021
Reinforcement of the therapeutic strategy to target the adaptive immune system to treat
external-link
Abata Therapeutics selects ABA-201 Treg cell therapy as development candidate for type 1 diabetes - BioWorld Online
external-link
Sept 2018
Demonstration that peripheral blood CD4+ T cells of MS patients can be analyzed to ide
external-link
Abata Therapeutics' Treg Therapy ABA-101 Garners FDA Fast Track Designation - CGTLive™
external-link
It was great speaking with ElevateBio about our ongoing manufacturing partnership, which expedited our lead program, ABA-101 for the treatment of progressive multiple sclerosis, and set up a template
external-link
Phase 1 trial of ABA-101 in progressive MS expected by year's end - Multiple Sclerosis News Today
external-link
Aug 1995
First identification of a suppressive T cell population – renamed regulatory T cells or
external-link
Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes - Business Wire
external-link
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
Press Release
external-link
Abata gets equity investment from Bristol Myers Squibb - BioWorld Online
external-link
Nov 2015
Demonstration that autologous human Tregs can be vastly expanded ex vivo, safely transf
external-link
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
external-link
How venture philanthropy is changing the game in drug development - The Business Journals
external-link
Third Rock-Seeded Abata Aims Tregs, $95 Million at Autoimmune Diseases - BioSpace
external-link
June 2021
Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulat
external-link
2007-2019
A series of genetic analyses demonstrated that the inherited susceptibility to MS was
external-link
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer - GlobeNewswire
external-link
Abata obtains IND clearance for autologous TCR-Treg therapy for progressive MS
external-link
Stable regulatory t cells and methods of production
external-link
What’s Tipping the Scale for Bioprocessing? - Genetic Engineering & Biotechnology News
external-link
AstraZeneca pays $85M to Quell Type 1 diabetes with 'one and done' cell therapy - Fierce Biotech
external-link
This weekend, the Abata team took part in the Breakthrough T1D Walk in Boston.
We are proud to join forces with the type 1 diabetes community to elevate awareness and champion research for T1D. By co
external-link
Abata hopes to find ‘perfect fit’ with MS cell therapy after $95M series A - Fierce Biotech
external-link
How Abata new strategy in non-relapsing MS? Third Rock leads $95M series A
external-link
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
Press Release
September 16, 2024
external-link
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
Press Release
external-link
Feb 2012
First demonstration that stable Tregs originate from the thymus before entering the blo
external-link
Aug 2018
Demonstration of heterologous/infectious tolerance in mouse EAE models of CNS inflammat
external-link
For the second year running, Samantha Singer, CEO, will be a panelist at #WMIF2024. This year, she’s participating in a panel discussion on the role of cell therapies for autoimmune diseases. We’re lo
external-link
Jan 2020
Demonstration that Tregs can be used to treat autoimmune disease in mice, when engineer
external-link
Are Cellular Therapies the Future of Autoimmune Disease?
Medscape
October 23, 2023
external-link
Harnessing regulatory T cells to establish immune tolerence
Science Translational Medicine
March 13, 2024
external-link
Today, our CSO Ellen Cahir-McFarland presented in vivo preclinical data on our lead program, ABA-101, indicating that our TCR-engineered Tregs are doing what they were designed to do. The data support
external-link
Jan 2019
Review: Targeting autoreactive T cells with Tregs is a valid therapeutic approach in MS
external-link
Aug 2019
First demonstration that chronic-active demyelinating lesions, a biomarker of ongoing i
external-link
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis - Yahoo Finance
external-link